The opportunistic pathogen Pneumocystis carini (Pc) is considered to be the leading cause of morbidity in patients with AIDS. It is important, therefore, to determine the immunological mechanisms of resistance to Pc. We have taken advantage of the lack of both T and B lymphocytes in severe combined immunodeficiency (scid) mice to determine the critical factors in resistance to spontaneously acquired Pc pneumonia. Invest. 1992.90:673-678.)
Introduction
Pneumocystis carini (Pc)' is the major diagnosed cause ofmorbidity in patients with AIDS (1), and has recently been reported to cause morbid pulmonary disease in mice homozygous for the recessive mutant gene scid (2) (3) (4) . Scid mice are essentially devoid offunctional T or B lymphocytes and both primary and secondary lymphoid tissues are rudimentary (5) (6) . The immune defects ofscid mice do not extend to macrophages (7) (8) , natural killer (NK) cells (9-1 1), or cells ofmyeloid lineage (12) .
Roths et al. (2) have described both positive and negative sequellae to reconstitution of scid mice with congenic normal bone marrow. Following marrow transfer, a formidable hyperinflammatory reaction (HIR) develops with 30% to 50% of these recipients becoming morbidly ill between 4 and 6 wk after transplantation. Of those that survive, resolution of the spontaneously acquired Pc pneumonia (PCP) is essentially complete. The present study was undertaken to define the role of antibody and specific lymphocyte subsets in the anti-Pneumocystis immune response.
Methods
Mice. The scid mutation was transferred by us to the inbred strain C57BL/6J (B6) by 10 backcrosses from the original C.B-17-scid/scid stock imported from the Institute for Cancer Research, Philadelphia, PA. Both C57BL/6J-scid/scid (B6-scid) (maintained by continued breeding of homozygotes) and its congenic normal partner strain C57BL/6J (B6) were propagated in a barrier breeding colony. At weaning, mice destined for experimental use were transferred to a conventional colony and remained there until necropsy. The husbandry and animal health characteristics of these colonies were similar to those described in detail in our original study of naturally acquired pneumocystosis in C.B-17-scid mice (2) . The extent (cyst density) and kinetics of infectivity by Pc and the time of morbidity caused by spontaneously acquired Pc pneumonia (PCP) in these mice are nearly identical to those described in that previous study. In brief, these mice have carried a stable and endemic Pc infection for more than 4 yr, developed plateau levels of organisms in -2 mo, lived an average of 5 mo, and were selected at random for inclusion in these studies.
Pc antigen preparation. Scid mouse lung digest (SMLD) was prepared from a large number of lungs obtained from sick scid mice (frozen at -70'C until needed) using a process similar to that described by Gradus and Ivey (13) . Infected lung was diced and passed through No. 60 wire mesh and collected in sterile HBSS (Gibco BRL, Grand Island, NY) supplemented with penicillin, streptomycin, and amphotericin B (Gibco). 10 mM of the wetting agent "G-acid" (2-naphthol-6-8-disulfonic acid, dipotassium; Eastman Kodak Co., Rochester, NY) were added to reduce clumping of Pneumocystis organisms. The 
Results
Adoptive transfer of Pc-sensitized and nonsensitized lymphocytesfrom B6 to B6-scid mice (experiment 1). Initially, we compared the effectiveness of titrated doses of LNC from either deliberately immunized or nonimmunized B6 immunocompetent donors upon transfer to congenic mutant B6-scid mice with spontaneous pneumocystosis. 5 million LNC from either donor were effective in eliminating Pc 4 wks after cell transfer ( Fig. 1 A) ; cyst density was reduced in both cases by > 98%. Ten times fewer LNC from immunized donors provided a 68% reduction, while an equal number of nonimmunized donor cells did not cause a significant reduction in Pc cyst density. Two orders of magnitude fewer LNC (5 x 104) from either source had no effect on the number ofPc cysts. However, the transfer of as few as 5 X 104 LNC from either donor was sufficient to cause a doubling of the lung mass of scid recipients ( Fig. 1 E) , and 5 X 105 LNC of either type yielded significant morbidity (Fig. 1 C) . Histologically, these lungs contained large numbers of "activated" mononuclear phagocytes and an accumulation of edema fluid within the alveoli. These findings are consistent with that of the hyperinflammatory reaction previously described (2) Adoptive transfer of lymphocyte subsets and passive HIS therapy (experiment 2). To determine which lymphoid cells other than or in addition to B cells are capable of exerting an effective anti-Pneumocystis response, we examined the separate capacities of immune serum (antibody) or FACS"-sorted CD4' or CD8' T cell subsets to provide an anti-Pc response (Fig. 2) . Unsorted spleen plus lymph node cells, as well as ALL LYM were effective in reducing Pc cyst densities to 9% and 16% ofcontrol (untreated) numbers, respectively. Similar numbers of sorted CD4' T cells reduced the cyst density to 5% of control, while transferred CD8' T cells were ineffective (Fig. 2 A). Animals treated with anti-Pc HIS once per week for 8 wk showed a significant reduction in Pc cysts (to 23% ofuntreated controls).
All recipients of unfractionated or CD4' lymphocytes (i.e., those transfers that cleared Pc from the lungs) had an increase in lung mass (Fig. 2 B) that was attributable to an extreme HIR (Fig. 3, A and B) . This process and the presence of well-differentiated lymphoid cells in the perivascular and peribronchial regions of the lung were identical to those described for scid recipients of immunocompetent bone marrow (2). The Pc levels and histological features of the lungs of scid recipients of CD8' T cells were indistinguishable from those of untreated (Pc infected) scid lungs (Fig. 3 C) . Morbidity correlated with effective Pc clearance and increased lung weights in recipients of immune lymphocytes, with the highest morbidity in recipients of CD4' T cells (80%) (Fig. 2 C) . In contrast to the results of cell transfer, HIS-treated scid mice suffered no mortality. The lungs of these mice did not show HIR, and in fact were reduced (by 37%) in weight compared to untreated controls (Fig. 2 B) , reflective of a striking reduction of Pc cysts, foamy matrix and numbers of macrophages. The septal interstitium appeared thin and alveoli increasingly clear in recipients of both hyperimmune serum and CD4' T cells (Fig. 3 D) .
As expected, recipients of HIS had significant elevations of anti-Pc antibody with a mean OD for the IgG2a class of 0.58 compared to 0.1 1 for untreated scidcontrols. None ofthe recipients of unfractionated or specific T cell subsets, which also effectively cleared Pc organisms, had detectable anti-Pc anti- Only one of these morbidly ill mice (C, 48 d) was not necropsied because of severe autolysis after death. Cyst density (A) and morbidity (C) analyses were done as described above (Fig. 1) and left lungs were dissected and weighed (B) before histological processing. body levels of either the IgM or IgG2a isotypes (data not shown).
Discussion
In the past, the role ofhumoral immunity in defense against Pc has been controversial because of findings of serum antibodies in both healthy individuals and patients with PCP (14) (15) . A series of patients with PCP has been described as being hypogammaglobulinemic but having intact T cell immunity (16) . Studies by Walzer and Rutledge have demonstrated serum antibody responses to Pc (17) . The partial success of passive immunoprophylaxis (using anti-Pc mAb) in protecting experimental animals against Pc (18) showed that humoral immunity can play a role in resistance to Pc.
A large body of evidence also indicates that T cells, and CD4+ T cells in particular, are required for resistance to PCP. The identification of Pc in athymic nu (nude) rats and mice (19) (20) (31) , and other studies in our laboratory have shown IgG2a to be the predominant isotype generated in mouse anti-Pc humoral responses (manuscript in preparation). Activated macrophages produce as well as respond to tumor necrosis factor-alpha (TNF-a) (32) . Pc has been shown to stimulate the in vitro production ofTNFa by human macrophages (33). A recent clinical study suggested that TNF-a produced by alveolar macrophages may play a major role in the control of PCP in AIDS patients (34) .
In addition to the enhancement of macrophage activation, TNF-a has been shown to be directly toxic to Pneumocystis (29).
The HIR-related morbidity associated with T-cell transfer, as well as the wasting syndrome associated with chronic pneumocystosis in scid mice, may reflect the known capacity of TNF-a to produce cachexia in vivo (35) and in patients with parasitic disease (36) . The fact that in vivo administration of IL-2, a cytokine produced by type 1 T helper (CD4+) cells (37) , results in increased microvascular permeability with resultant pulmonary edema (38) provides a possible mechanistic explanation for our finding of intraalveolar fluid accumulation during HIR following T cell transfer to Pc-infected scid mice. The Our histological analysis of scid recipients of unsorted or sorted CD4+ T cells found well-differentiated lymphocytes located primarily in the perivascular and peribronchial regions of the lung. Studies by Breel et al. (41) have shown that the bronchus-associated lymphoid tissue ofmice is populated by macrophages and lymphocytes, with the majority ofT cells belonging to the CD4+ subset. This localization suggests that both the host-beneficial and -harmful effects of anti-Pc CD4+ T cells may be expressed "at a distance" rather than by direct contact in the affected parenchyma. Ongoing efforts are thus directed at studying the effects and role ofaction ofcytokines (especially IFN--y and TNF-a) in response to Pneumocystis in scid mice.
Most generally, the results reported here dramatically illustrate the nature of the immune system as a "double-edged sword" capable of either protecting or harming its host. CD4+ T cells may be particularly noteworthy in this regard since they produce a broad range ofcytokines involved in both protection ofthe host and immunopathological processes. These observa-tions provide a possible theoretical basis for the paradoxical and surprising benefits of administering immunosuppressive steroids to already immunocompromised AIDS patients in respiratory failure due to PCP (42) , and suggest that both enhancing and suppressing the activity of the immune system should be considered as therapies in immunological disease.
